stockrow
Saturday 7 November 2026
Export EIKN’s income statement to Excel — free account
Eikon Therapeutics, Inc.
EIKN Healthcare Biotechnology
5.92
0.08
+1.37%
Follow EIKN
Alert me
| Jun '26 | Mar '26 | Dec '25 | Jun '25 | Older periods | |
|---|---|---|---|---|---|
| 0.00% | — | — | — |
+2 more TTM periods Free account |
|
| (90.08%) | 0.00% | — | — | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(56.20%) | 0.00% | 0.00% | — | |
Free Cash Flow per Share |
(8.22) | (13.55) | 0.00 | 0.00 | |
Free Cash Flow |
(444.98) | (456.65) | (586.19) | — | |
Capital Expenditures |
(68.97) | (91.08) | (175.62) | — | |
| Other line items | |||||
Cash ROIC |
(44.58%) | (42.95%) | 108.02% | 0.00% | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | — | |
Tax Rate |
0.00 | — | — | — | |
Research and Development Expense of Revenue |
0.00% | — | — | — | |
Selling, General and Administrative Expense of Revenue |
0.00% | — | — | — | |
Share Based Compensation of Revenue |
0.00% | — | — | — | |
Operating CF/Net income |
1.07 | 0.00 | 0.00 | — | |
Depreciation/Fixed assets |
0.31 | 0.30 | 0.44 | — | |
Capex/Depreciation |
(1.70) | (2.17) | (2.82) | — | |
Revenue per Share |
0.00 | 0.00 | — | 0.00 | |
Operating CF per Share |
(6.94) | (10.85) | 0.00 | 0.00 | |
Capex per Share |
(1.27) | (2.70) | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | — |
Columns are period end dates · fundamentals updated 25 Oct 2026